IRADIMED CORP (IRMD) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. IRADIMED CORPORATION develops, manufactures, and distributes MRI-compatible medical devices, including IV infusion pumps, patient vital signs monitoring systems, and ferromagnetic detection systems. The company operates as a single reportable segment serving hospitals and acute care facilities primarily in the United States and internationally.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $19.51 million | $17.60 million |
| Gross Profit | $14.84 million | $13.39 million |
| Gross Margin | 76.1% | 76.1% |
| Net Income | $4.69 million | $4.14 million |
| Diluted EPS | $0.37 | $0.32 |
| Cash and Equivalents | $50.33 million | $45.13 million |
| Working Capital | $66.66 million | $66.73 million |
| Operating Cash Flow | $4.29 million | $3.88 million |
| Capital Expenditures | $3.92 million | $0.48 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11% year-over-year, driven by a 19% increase in U.S. sales ($15.95M vs. $13.41M) and a 23% increase in disposable product sales. International revenue declined 15% to $3.56M.
- Expense Trends: Operating expenses rose 9% to $9.41M. General and Administrative (G&A) expenses increased 15% due to higher legal, professional, and payroll costs. Sales and Marketing expenses increased 11%. Conversely, R&D expenses decreased 25% due to reduced prototype material purchases.
- Investing Activity: Cash used in investing activities surged to $3.92M (from $0.48M in Q1 2024), primarily attributed to construction costs for a new corporate office and manufacturing facility in Orange County, Florida.
- Dividends: Dividends paid decreased significantly to $2.16M in Q1 2025 compared to $7.98M in Q1 2024, which included a special dividend payment in the prior year.
Outlook, Risks, and Management Commentary
- Guidance: Management expects higher revenue for the remainder of fiscal year 2025 compared to the same period in 2024, driven by increased sales of devices, accessories, and disposables. Operating expenses are also expected to be higher due to increased sales, marketing, regulatory, and G&A costs.
- Trade Policy Risks: The company highlights significant risks related to recent U.S. trade policy changes, including tariffs on imports from China, Canada, and Mexico. These tariffs may increase production costs, necessitate price increases, or disrupt the supply chain.
- Regulatory & Operational: Key risks include the ability to obtain FDA 510(k) clearances for new products, reliance on sole-sourced components, and potential supply chain disruptions. The company is currently under IRS examination for the tax year ended December 31, 2021.
- Liquidity: The company maintains a strong liquidity position with $50.3M in cash and a $75M shelf registration statement available for equity offerings. Management believes current cash and operating cash flows are sufficient for the next 12 months.
Investor Verification Checklist
- Verify the timeline and cost impact of the new manufacturing facility construction in Orange County, Florida.
- Monitor the specific impact of new U.S. tariffs on the cost of raw materials and component sourcing.
- Review the status of the IRS examination for the 2021 tax year for potential adjustments.
- Track the progress of international revenue recovery, which declined 15% in Q1 2025.
- Confirm the schedule for FDA 510(k) clearances for any pending product candidates.